<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03840928</url>
  </required_header>
  <id_info>
    <org_study_id>GlobalHealthyLivingF</org_study_id>
    <nct_id>NCT03840928</nct_id>
  </id_info>
  <brief_title>AR-Power Patient Powered Research Network</brief_title>
  <acronym>GHLF</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Global Healthy Living Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Global Healthy Living Foundation</source>
  <brief_summary>
    <textblock>
      ArthritisPower is a patient research network and database (registry) to collect prospective
      information about demographics, self-reported diagnoses and medications, and willingness to
      participate in research from participants with rheumatoid arthritis (RA), spondyloarthritis
      (SpA), and other musculoskeletal conditions. Participants will provide information from their
      smartphones or personal computers. The information will be used by researchers to help
      patients and their providers make better, more informed decisions about treatment of RA/SpA
      and other musculoskeletal conditions. ArthritisPower is part of a larger national research
      network called PCORnet whose 33 network members have mapped their data to a common data
      model. Network members will be able to submit queries through PCORnet in order to answer a
      range of comparative effectiveness research questions. Data sharing across PCORnet will be
      accomplished using secure methods to prevent patient identification. There is no cost to
      participants for participating and no compensation is provided.

      Objectives:

        1. To establish a research registry to enable comparative effectiveness research in
           rheumatic diseases and other musculoskeletal conditions. All data collected using the
           ArthritisPower mobile app as part of a subject's use is stored with the ArthritisPower
           registry. This data will be used in conjunction with existing and future research
           studies.

        2. To use the data from this study to improve treatment and to further advance finding a
           cure for rheumatic diseases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2015</start_date>
  <completion_date type="Anticipated">March 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Pain Interference (PROMIS)</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fatigue (PROMIS)</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep Disturbance (PROMIS)</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Function (PROMIS)</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>RAPID-3 (MD-HAQ with visual analogue scale for pain and patient global measure for overall health)</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <number_of_groups>13</number_of_groups>
  <enrollment type="Anticipated">9867</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Fibromyalgia</condition>
  <condition>Gout</condition>
  <condition>Crohn Disease</condition>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <condition>Lupus Erythematosus</condition>
  <condition>Myositis</condition>
  <condition>Osteoarthritis</condition>
  <condition>Osteoporosis</condition>
  <condition>Psoriasis</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Scleroderma</condition>
  <arm_group>
    <arm_group_label>Ankylosing Spondylitis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Fibromyalgia</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Gout</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Crohn's-related Arthritis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Juvenile Idiopathic Arthritis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Lupus</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Myositis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Osteoarthritis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Osteoporosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriasis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriatic Arthritis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Scleroderma</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be derived from the population of people who indicate that they have been
        diagnosed by a physician as having musculoskeletal conditions including RA, SpA and other
        chronic musculoskeletal conditions. These will come from two sources:

          1. CreakyJoints website, an online rheumatic-disease patient support community
             (www.CreakyJoints.org), composed of patients with arthritis and arthritis-related
             disease, CreakyJoints members with self-reported musculoskeletal conditions will be
             invited to join the ArthritisPower research registry and download the ArthritisPower
             App.

          2. CreakyJoints Facebook and Twitter social network platforms. CreakyJoints &quot;fans&quot; or
             &quot;followers&quot; will be told about the ArthritisPower registry and app on the CreakyJoints
             Facebook page (www.Facebook.com/CreakyJoints) and/or Twitter account
             (https://twitter.com/creakyjoints).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 19 and above. We will only allow Puerto Rican residents to join if they are 21 or
             older. We will add conditional logic in the registration to ensure that Puerto Ricans
             under the age of 21 cannot complete the registration and participate in
             ArthritisPower.

          2. Self-report that a physician has given a diagnosis of RA, SpA, or other
             musculoskeletal condition.

          3. The Registry is only intended at this time for residents of the United States and
             United States territories who are nineteen (19) years or older (for Puerto Rico
             residents, you must be 21 years or older to participate).

        Exclusion Criteria:

        a) Age &lt; 19 years b) No self-reported physician diagnosis of musculoskeletal condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ben Nowell, PhD</last_name>
    <email>bnowell@ghlf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachael Langa</last_name>
    <email>rlanga@ghlf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Global Healthy Living Foundation</name>
      <address>
        <city>Upper Nyack</city>
        <state>New York</state>
        <zip>10960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>February 12, 2019</last_update_submitted>
  <last_update_submitted_qc>February 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Global Healthy Living Foundation</investigator_affiliation>
    <investigator_full_name>Ben Nowell</investigator_full_name>
    <investigator_title>Director, Patient-Centered Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

